Camber Adds 800 mg Darunavir Tablets to Product Family
Camber Pharmaceuticals continues to expand its portfolio of HIV treatments with the addition of 800 mg Darunavir Tablets [da-ROON-a-veer], supplied in bottles of 30.
This new strength joins Camber’s previously launched 600 mg Darunavir Tablets, introduced two years ago. Darunavir Tablets are the generic equivalent of Prezista®.
Darunavir Tablets co-administered with ritonavir (darunavir tablets/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older.
To learn more about this product, visit: www.camberpharma.com/darunavir
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection





